Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05726916

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome (HYPERSHU)

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome: a Randomized Multicenter Controlled Trial

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Interventions Renin angiotensin system blockers Soliris®

Updated 6 times since 2023 Last updated: Jan 2, 2024 Started: Nov 9, 2023 Primary completion: May 9, 2026 Completion: Nov 9, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypertensive Emergency-associated Hemolytic Uremic Syndrome and is currently actively recruiting participants. Assistance Publique - Hôpitaux de Paris leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2023 — Feb 2024 [monthly]

Not Yet Recruiting PHASE3
May 2023 — Oct 2023 [monthly]

Not Yet Recruiting PHASE3

▶ Show 1 earlier version

Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France